Boniva®, a bisphosphonate, is a prescription drug used to treat or prevent bone-loss. Boniva® and other bisphosphonate drugs have recently been linked to atypical femur fractures. The femur, or thigh bone, is considered the strongest bone in the body. Women who have been taking Boniva® for an extended period of time are experiencing thigh fractures at an alarming rate, including many reports of women who have broken their femur while walking.
It is not yet known how Boniva® and other bisphosphonates, drugs that are supposed to strengthen bones, are somehow weakening the femur. One study suggests that Boniva® and bisphosphonate drugs may interfere in the replacement of bone tissue, causing bones to be brittle. Other experts think that bisphosphonates may be making bones too hard, making them susceptible to fracture.
The United States Food and Drug Administration has acknowledged that there may be a link between bisphosphonates and atypical fractures of the femur. Legal action against the makers of Boniva®, Roche Therapeutics, are currently ongoing.